Deferoxamine intranasal - Sanomune

Drug Profile

Deferoxamine intranasal - Sanomune

Alternative Names: SAN-121

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HealthPartners Research Foundation
  • Developer Sanomune
  • Class Hydroxamic acids; Small molecules
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in USA (Intranasal)
  • 30 Jun 2010 Sanomune has been acquired by DiaMedica
  • 06 Mar 2009 Preclinical trials in Alzheimer's disease in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top